Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma

PURPOSE: Enhancer of zeste homolog 2 (EZH2), a chromatin remodeler, is implicated in the pathogenesis of clear cell renal cell carcinoma (ccRCC). However, the effect of EZH2 on outcomes in localized ccRCC is unclear, and molecular biomarkers are not currently integrated into prognostic models or adj...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Ho, Thai Huu, Kapur, Payal, Eckel-Passow, Jeanette E., Christie, Alana, Joseph, Richard W., Serie, Daniel J., Cheville, John C., Thompson, R. Houston, Homayoun, Farrah, Panwar, Vandana, Brugarolas, James, Parker, Alexander S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5678341/
https://ncbi.nlm.nih.gov/pubmed/28976794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.3238
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados